Journal
CELL
Volume 182, Issue 4, Pages 843-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2020.06.044
Keywords
-
Categories
Funding
- Klein Laboratory
- Becker Laboratory
- German Center for Infection Research (DZIF)
- German Research Foundation (DFG) [CRC 1279, CRC 1310, FOR2722, EXC 2064/1, 390727645]
- European Research Council [ERC-StG639961]
- German Federal Ministry of Education and Research (BMBF) within the Medical Informatics Initiative (DIFUTURE) [01ZZ1804D]
- Ben B. and Joyce E. Eisenberg Foundation
- Ernst I. Ascher Foundation
Ask authors/readers for more resources
The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and the world economy. Because approved drugs and vaccines are limited or not available, new options for COVID-19 treatment and prevention are in high demand. To identify SARS-CoV-2-neutralizing antibodies, we analyzed the antibody response of 12 COVID-19 patients from 8 to 69 days after diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days after diagnosis. Of these, 28 potently neutralized authentic SARS-CoV-2 with IC100 as low as 0.04 mu g/mL, showing a broad spectrum of variable (V) genes and low levels of somatic mutations. Interestingly, potential precursor sequences were identified in naive B cell repertoires from 48 healthy individuals who were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available